Investigating the role of JAK inhibition in achieving and maintaining disease remission in psoriatic arthritis (PsA).
This study is investigating a medicine called XELJANZ for people with psoriatic arthritis, a condition that causes sore joints and skin problems. Researchers want to see if XELJANZ can help patients achieve remission, meaning their symptoms significantly improve or disappear. They're also interested in whether people can stay in remission, even after stopping the medicine. The study will track various aspects of the condition, including joint pain, swelling, skin issues, and overall quality of life over two years. This is a Phase IV study, meaning the medicine is already approved for use, and researchers are gathering more information about its long-term effects and how it helps patients in real-world settings.
De un vistazo
¿De qué trata este estudio?
This study is all about understanding how a medicine called XELJANZ works for people living with psoriatic arthritis (PsA). PsA is a type of arthritis that can cause painful and swollen joints, as well as skin problems like psoriasis. The main goal of this research is to see if XELJANZ can help people with PsA get into remission, which means their symptoms are much better or have even gone away. They also want to understand if people can stay in remission after they stop taking the medication.
To do this, the research team will carefully track different things over more than two years. They'll look at how your joints, fingers and toes (dactylitis), and areas where tendons attach to bone (enthesitis) are doing. They'll also check your skin. Beyond physical symptoms, the study will ask about your everyday life and how you feel, for example, your ability to do daily activities and your overall well-being. This helps them understand the full impact of the medicine on your life.
This is called a 'Phase IV' study. This means that XELJANZ is already a medication approved for use, but doctors want to learn more about how it works in real-world situations for many different patients. By doing this research, they hope to get a clearer picture of its long-term benefits and how it can best help people with psoriatic arthritis manage their condition.
Puntos clave
- This study explores how XELJANZ helps psoriatic arthritis.
- It aims to see if the medicine can lead to and maintain remission.
- Researchers will track joint, skin, and overall well-being for over two years.
- Participation involves taking XELJANZ and attending regular check-ups.
- It's a Phase 4 study, gathering more information on an already approved medicine.
¿Quién puede ser elegible?
To be part of this study, you need to be at least 18 years old. Both men and women can take part.
You would likely be considered if you have psoriatic arthritis and meet other specific requirements related to your health and treatment history. These details would be checked by the study team to ensure the study is right for you, and that you meet the necessary health criteria for safe participation.
It's important to remember that these are just the basic age and gender rules. There will be other medical criteria to check if this study is a good fit for you. Your doctor will discuss all of these with you carefully.
¿Podría este estudio ser adecuado para ti?
Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.
- ¿Tengo 18 años o más?
- Do I have a diagnosis of psoriatic arthritis?
- Am I able to attend regular clinic visits for about two years?
- Am I comfortable taking study medication and filling out questionnaires?
¿En qué consiste la participación?
If you decide to take part in this study, you would be taking XELJANZ film-coated tablets as prescribed by the study doctors. Over the course of the study, which lasts for about two years (104 weeks), you would have regular visits to the clinic. These visits would happen at specific times, like at week 4, 12, 24, 28, 52, 76, and 104.
During these visits, the study team would check your health in several ways. This might include checking your joints, measuring any swelling in your fingers or toes, and looking at your skin. You would also be asked to fill out questionnaires about how you are feeling and how your condition affects your daily life. They will also collect information to track how your disease changes over time, including looking at your bone health.
The study aims to see if you can achieve remission and potentially stay in remission even after stopping the medication. The total duration of active follow-up would be until week 104.
Riesgos y beneficios potenciales
Ubicaciones (1)
- —No verificadoBélgica
Preguntas comunes
What is psoriatic arthritis?
Psoriatic arthritis is a long-term condition that causes painful, swollen joints and can also affect the skin, causing psoriasis rashes.
What does 'remission' mean in this study?
Remission means that the symptoms of your psoriatic arthritis have significantly improved or are no longer present.
What is XELJANZ?
XELJANZ is a medicine that is already approved for use, but this study wants to learn more about how it helps people with psoriatic arthritis over time.
How long will I need to be in the study?
The study will last for about two years, with regular check-ups at the clinic during that time.
Can anyone join this study?
You need to be at least 18 years old. Beyond that, the study team will check other health details to see if it's the right fit for you.
Cómo obtener más información
Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.
¿Interesado en participar?
Discusión
Discusión comunitaria
Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.